+1.30 %
-15.22 %
-11.16 %
-33.33 %
-23.53 %
-11.86 %
-0.95 %
-39.02 %
-84.51 %
Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096 is a small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. HER-096 combines the mechanism of action of CDNF with subcutaneous administration. The Phase 1a clinical trial demonstrated a good safety and tolerability profile as well as blood-brain barrier penetration of subcutaneously administered HER-096. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.
Read moreMarket cap
41.35M EUR
Turnover
39.7K EUR
P/E (adj.) (26e)
-12.67
EV/EBIT (adj.) (26e)
-10.85
P/B (26e)
5.32
EV/S (26e)
4,437.64
Dividend yield-% (26e)
-
